Combination Therapies in Melanoma

November 5, 2013
Omid Hamid, MD

Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses promising combination therapies for the treatment of melanoma.

Clinical Pearls

  • In the metastatic setting, BRAF, MEK, and checkpoint inhibition is forthcoming
  • There are currently trials looking at anti-PD-1 with anti-CTLA-4 therapy
  • Dr. Hamid is hopeful that in the future, other targeted immunotherapies and FDA-approved targeted treatment combinations will show survival benefit and be approved and available for use.